10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

DEDD2 Antibody

Catalog # ASC10180

Product Information

Application	WB, E
Primary Accession	Q8WXF8
Other Accession	NP_579874, 19923050
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	36179
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	DEDD2 antibody can be used for detection of DEDD2 by Western blot at 0.5 to 2 □g/mL.

Additional Information

Gene ID	162989
Other Names	DEDD2 Antibody: FLAME-3, FLAME3, PSEC0004, DED-containing protein FLAME-3, death effector domain containing 2
Target/Specificity	DEDD2;
Reconstitution & Storage	DEDD2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Precautions	DEDD2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	DEDD2
Synonyms	FLAME3
Function	May play a critical role in death receptor-induced apoptosis and may target CASP8 and CASP10 to the nucleus. May regulate degradation of intermediate filaments during apoptosis. May play a role in the general transcription machinery in the nucleus and might be an important regulator of the activity of GTF3C3.
Cellular Location	Nucleus, nucleolus. Note=Nuclear, accumulated in subnuclear structures resembling nucleoli

Tissue Location	Expressed in most tissues. High levels were found in liver, kidney, heart, ovary, spleen, testes, skeletal muscle and peripheral blood leukocytes. Expression was absent or low in colon and small intestine. Expression is relatively high in the tumor cell lines chronic myologenous leukemia K-562 and the colorectal adenocarcinoma SW480. Expression is moderate in the cervical carcinoma HeLa, the Burkitt's lymphoma Raji, the lung carcinoma A-549, and the melanoma G- 361. In contrast, two leukemia cell lines, HL-60 (promyelocytic leukemia) and MOLT-4 (lymphoblastic leukemia), show relatively low levels.


Background

DEDD2 Antibody: Apoptotic signals are often triggered by cell surface death receptors through protein-protein interactions mediated by conserved domains such as the death effector domain. A novel death effector domain (DED)-containing protein, DEDD2, has been recently identified and its over-expression in transfected cells induces moderate apoptosis and results in substantial sensitization to apoptosis induced by Fas, TRAIL, and FADD. More recently, work has shown that DEDD2 can bind caspase-8 and -10 in addition to FLIP but not FADD. Like the related protein DEDD, DEDD2 translocates from the cytosol to the nucleus upon induction of apoptosis, and it has been suggested that DEDD2 may target caspase-8 to the nucleus and that DEDD2 thus plays a critical role in death receptor-induced apoptosis. At least two alternatively spliced transcript variants encoding distinct isoforms have been found for DEDD2.

References

Tibbetts MD, Zheng L, and Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat. Immunol. 2003; 4:404-9.
Roth W, Stenner-Liewen F, Pawlowski K, et al. Identification and characterization of DEDD2, a death effector domain-containing protein. J. Biol. Chem. 2002; 277:7501-8.
Alcivar A, Hu S, Tang J, et al. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene 2003; 22:291-7.

Images



Western blot analysis of DEDD2 in RAW264.7 cell lysate with DEDD2 antibody at (A) 0.5, (B) 1 and (C) 2 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.